CHD4 drives gastric cancer metastasis via MYH9/GSK3β/β-catenin axis and WNT/EMT pathway activation
Cancer Letters · 2025-09 · 628 · 217813
DOI: 10.1016/j.canlet.2025.217813 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2025-09. Verfasst von Yuntao Shi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Digestive Diseases Center, The Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen, 518107, China; Guangdong Provincial Key Laboratory of…. Hauptthemen laut MEDLINE: Stomach Neoplasms, Epithelial-Mesenchymal Transition, Myosin Heavy Chains, beta Catenin. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 66 Literaturangaben. Gefördert von: Basic and Applied Basic Research Foundation of Guangdong Province, Sanming Project of Medicine in Shenzen Municipality.
Abstract (Originalsprache)
Gastric cancer (GC) metastasis remains a significant cause of cancer-related mortality, yet the molecular mechanisms underlying this process have not been fully elucidated. CHD4, a chromatin remodeling factor, has been associated with oncogenic processes, but its precise role in GC metastasis has not been defined. In this study, we identify CHD4 as a critical regulator of GC metastasis through the MYH9/GSK3β/β-catenin axis and the activation of the WNT pathway and epithelial-mesenchymal transition (EMT). Clinically, CHD4 was significantly overexpressed in GC tissues and strongly correlated with advanced disease stages and poor prognosis. Mechanistically, CHD4 interacted with MYH9 via its ATPase domain and promoted the nuclear-to-cytoplasmic translocation of MYH9, thereby enabling MYH9 to orchestrate inhibitory phosphorylation and ubiquitination-dependent degradation of GSK3β. This, in turn, stabilized β-catenin, leading to its nuclear accumulation and activation of downstream WNT target genes, such as Cyclin D1, along with the induction of EMT. Functionally, suppression of CHD4 expression inhibited GC cell migration, invasion, and metastasis in vivo, while MYH9 restoration reversed these effects. Collectively, these findings establish CHD4 as a key regulator of GC metastasis through the MYH9/GSK3β/β-catenin axis and underscore its potential as a therapeutic target for inhibiting GC progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Digestive Diseases Center, The Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen, 518107, China; Guangdong Provincial Key Laboratory of Digestive Cancer Research, The Seventh Affiliated Hospital of Sun Yat…
- Digestive Diseases Center, The Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen, 518107, China.
- Department of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, United States. Electronic address: Zhijun-Zhou@ouhsc.edu.
Förderung
- Basic and Applied Basic Research Foundation of Guangdong Province
- Sanming Project of Medicine in Shenzen Municipality
Zitieren
APA
Shi, Y., Zhao, Z., Zhou, S., Zhou, Z., Huang, Z., Zhou, Z., & Zhang, C. (2025). CHD4 drives gastric cancer metastasis via MYH9/GSK3β/β-catenin axis and WNT/EMT pathway activation. Cancer Letters, 628, 217813. https://doi.org/10.1016/j.canlet.2025.217813
Vancouver
Shi Y, Zhao Z, Zhou S, Zhou Z, Huang Z, Zhou Z, et al. CHD4 drives gastric cancer metastasis via MYH9/GSK3β/β-catenin axis and WNT/EMT pathway activation. Cancer Letters. 2025;628:217813. doi:10.1016/j.canlet.2025.217813
BibTeX
@article{Shi2025,
author = {Shi, Yuntao and Zhao, Zidan and Zhou, Shangbo and Zhou, Ziwen and Huang, Zhangsen and Zhou, Zhijun and Zhang, Changhua},
title = {CHD4 drives gastric cancer metastasis via MYH9/GSK3β/β-catenin axis and WNT/EMT pathway activation},
journal = {Cancer Letters},
year = {2025},
volume = {628},
pages = {217813},
doi = {10.1016/j.canlet.2025.217813}
}
EUVIMED